| Name | Title | Contact Details |
|---|
Established in 1968, Providence Community Health Centers, Inc. is the largest primary health care provider in Providence, Rhode Island. In addition to eight health centers, we also operate a school-based program, and a dental clinic serving children under the age of 19 and pregnant women. PCHC is a non-profit health care organization and the only Federally Qualified Heath Center (FQHC) in Providence. We have recruited some of the area`s most prestigious physicians and empowered them to make a difference providing quality care to more than 50,000+ residents of Providence and its surrounding areas. As we continue to grow our network of neighborhood-based clinics, PCHC is seeking physicians to join our team. Our services include: Family Practice, Internal Medicine, Pediatrics, Obstetrics, Gynecology, Behavioral Health, Dental Care and Express Care (urgent care) alongside with selected specialty services.
Patterson Medical is a Columbia, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Western Missouri Medical Center (WMMC) is a fully-accredited acute care facility located in Warrensburg, Missouri. A not-for-profit county Medical Center, WMMC offers comprehensive health care services to residents of Johnson County and west central Missouri. Through collaborating with our medical staff and integrating advanced technology, WMMC continues to grow as a progressive Medical Center that will continue to meet the evolving needs of the greater community.
Smart devices and digital support that connect patients to care, with clinically-proven results https://t.co/zoMxznOfwA
ClarVista Medical` based in Aliso Viejo` California is a leading developer of innovative products to treat challenging ophthalmic conditions. In 2012 and in conjunction with series A financing` ClarVista was spun out from Prospex Medical` a medical device incubator` to pursue the development of the HARMONI™ IOL. Between 2012 and 2014` the company developed the first generation HARMONI™ system` conducted thorough first-in-human clinical study and developed a broad portfolio of intellectual property. In 2015 the company closed on a series B financing of $14M which will be used to develop the second generation HAROMONI™ system` conduct a larger feasibility clinical trial and obtain key regulatory approvals including CE mark and US IDE.